Sensei Biotherapeutics (NASDAQ:SNSE) Posts Quarterly Earnings Results, Beats Expectations By $1.07 EPS

Sensei Biotherapeutics (NASDAQ:SNSE) posted its earnings results on Monday. The company reported ($3.74) earnings per share for the quarter, topping the consensus estimate of ($4.81) by $1.07, FiscalAI reports.

Sensei Biotherapeutics Stock Performance

Sensei Biotherapeutics stock opened at $27.68 on Monday. The company has a market capitalization of $34.88 million, a P/E ratio of -1.45 and a beta of -0.14. Sensei Biotherapeutics has a fifty-two week low of $5.00 and a fifty-two week high of $36.76. The stock has a 50-day simple moving average of $21.21 and a 200-day simple moving average of $13.77.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. Renaissance Technologies LLC grew its holdings in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 10.6% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 11,516 shares of the company’s stock after buying an additional 1,100 shares during the period. Renaissance Technologies LLC owned 0.91% of Sensei Biotherapeutics worth $123,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 10.50% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on SNSE shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Monday, December 29th. Wall Street Zen upgraded shares of Sensei Biotherapeutics to a “hold” rating in a report on Saturday, December 27th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $30.00.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.